Skip to main content
. 2023 Oct 31;10(6):1753–1768. doi: 10.1007/s40744-023-00609-2

Table 3.

Therapy patterns for IL-6Ri and JAKi initiators between initiation and the 6-month follow-up visit

Therapy status at 6 months IL-6Ri initiators JAKi initiators
All initiations, N 100 129
Remain on therapy, NR (% of N) 71 (71%) 97 (75%)
Discontinue therapy, ND (% of N) 29 (29%) 32 (25%)

IL-6Ri interleukin-6 receptor inhibitors, JAKi Janus kinase inhibitors, N number of patients